| | Author and Year | Reference | Expression profile | | Positive expression | Negative expression |
| | Gronthos et al. 2001 | [15] | CD9, CD10, CD13, CD29, CD34, CD44,
CD49d, CD49e, CD54, CD55, CD59,
CD105, CD146, CD166, HLA-ABC | CD11a, CD11b, CD11c, CD31,
CD45, CD50, CD56, CD62e,
HLA-DR | | Zuk et al. 2001 | [1] | CD13, CD29, CD44, CD49d, CD71, | CD14,CD16, CD31,CD34, CD45, | | Zuk et al. 2002 | [21] | CD90, CD105, STRO-1, SH3 | CD56, CD62e, CD104, CD106, SMA | | Katz et al. 2005 | [20] | CD29, CD49b, CD49d, CD49e, CD51,
CD61, CD90, CD138, CD140a | CD11a, CD11b, CD11c, CD18,
CD41a, CD49f, CD62L, CD62P,
CD106, CD117, CD133, HLA-DR, ABCG2 | | Mitchell et al. 2006 | [16] | CD13, CD29, CD34, CD44, CD49a,
CD63, CD73, CD90, CD146, CD166 | CD31, CD144 | | Yoshimura et al. 2006 | [17] | CD34, CD90 | CD31, CD45, CD105, CD146 | | Oedayrajsingh-Varma et al. 2007 | [18] | CD34, CD54, CD90, CD105, CD117,
HLA-ABC, HLA-DR | CD31, CD45, CD106, CD146,
CD166 | | Zannettino et al. 2008 | [19] | CD44, CD90, CD105, CD106,
CD146, CD166, STRO-1, 3G5 | CD14, CD31, CD45 | | Traktuev et al. 2008 | [27] | CD10, CD13, CD34, CD90, CD140a,
CD140b, SMA | CD31, CD45, CD144 | | Zimmerlin et al. 2010 | [26] | CD34, CD90 | CD31, CD146, SMA | | Lin et al. 2008 | [25] | CD34 | CD31, CD140b, SMA |
| | Proposed phenotype of ASCS | CD13, CD29, CD34, CD44, CD49d, | CD11a, CD11b, CD11c, CD14, | | (common between two or more studies) | CD54, CD90, CD140a, HLA-ABC | CD31, CD45, CD106, CD144 | | Controversial markers in ASCs | CD105, CD140b, CD146, CD166, SMA, HLA-DR | |
| | Stromal cell markers | CD29, CD44, CD73, CD90, CD166 | | | Hematopoietic markers | CD31, CD34, CD45, ABCG2 | | | Pericyte markers | CD146, Stro-1, 3G5 | |
|
|
